Market Overview

UPDATE: Dawson James Initiates Spectrum Pharmaceuticals at Market Outperform on Share Weakness


Dawson James initiated coverage on Spectrum Pharmaceuticals (NASDAQ: SPPI) with a Market Outperform rating and a $15 price target.

Dawson James noted, "Spectrum is a mid-cap, oncology/hematology focused biotechnology company with a rich portfolio of marketed and development stage drugs. … Spectrum stock is currently trading at $11-12 range, and has dropped >37% from its 52- week high of $17.48. From a valuation standpoint, the shares trade at 2.1 times FY12 and 1.6 times FY13 revenues, and <6 and <4 times our FY12 and FY13 EPS estimates, levels more commonly associated with shares of manufacturers of generic drugs. We consider the recent weakness in stock an excellent buying opportunity for investors."

Spectrum Pharmaceuticals closed at $11.28 on Monday.

Latest Ratings for SPPI

Dec 2019MaintainsBuy
Dec 2019DowngradesBuyNeutral
Dec 2019DowngradesOverweightNeutral

View More Analyst Ratings for SPPI
View the Latest Analyst Ratings

Posted-In: Dawson JamesAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (SPPI)

View Comments and Join the Discussion!

Latest Ratings

TSCOPiper SandlerMaintains119.0
UNPBMO CapitalMaintains200.0
UNPArgus ResearchMaintains205.0
ISRGJP MorganMaintains665.0
EHTHRBC CapitalMaintains132.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at